Cetuximab

9 Topics Found
Cetuximab Drug Index

Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is distributed under the trade name Erbitux in the U.S. and Canada by the drug company Eli Lilly and Co. and outside those countries by the drug company Merck KGaA. In Japan, Merck KGaA, Bristol-Myers Squibb and Eli Lilly have a co-distribution. ...

I was wondering if anyone else has taken this medication and if they got a rash. How bad was it and how did you cope ? ## Hello, Susan! How are you? Yes, that is listed as one of the more serious and most common side effects of it, though it's noted that it rarely resulted in dose changes or stopping of the medication. It is usually reversible. Have you consulted your doctor to see what they advise that you do for it?

1 REPLY Filed under Cetuximab
Erbitux Cetuximab

Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is distributed under the trade name Erbitux in the U.S. and Canada by the drug company Eli Lilly and Co. and outside those countries by the drug company Merck KGaA. In Japan, Merck KGaA, Bristol-Myers Squibb and Eli Lilly have a co-distribution. ...

Alunbrig Brigatinib

Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc.[1] Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.[medical citation needed] Brigatinib could overcome resistance to osimertinib conferred by the EGFR C797S mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab.&am...

Brigatinib Drug Index

Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc.[1] Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.[medical citation needed] Brigatinib could overcome resistance to osimertinib conferred by the EGFR C797S mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab.&am...

NDC 66733-948 NDC Database

Erbitux 2 mg/ml Intravenous Solution by Imclone LLC ## Package Codes: 66733-948-23 ## Active Ingredients: Cetuximab

NDC 66733-958 NDC Database

Erbitux 2 mg/ml Intravenous Solution by Imclone LLC ## Package Codes: 66733-958-23 ## Active Ingredients: Cetuximab

NDC 65044-7462 NDC Database

Erbitux 2 mg/ml Intravenous Solution by Jubilant Hollisterstier LLC ## Package Codes: 65044-7462-1 ## Active Ingredients: Cetuximab

NDC 65044-7463 NDC Database

Erbitux 2 mg/ml Intravenous Solution by Jubilant Hollisterstier LLC ## Package Codes: 65044-7463-1 ## Active Ingredients: Cetuximab

Can't find what you're looking for?